<DOC>
	<DOCNO>NCT00742144</DOCNO>
	<brief_summary>This open-label study evaluate safety , tolerability , efficacy PK profile ofatumumab monotherapy Japanese follicular lymphoma ( FL ) chronic lymphocytic leukemia ( CLL ) patient . subject receive ofatumumab 8 weekly infusion .</brief_summary>
	<brief_title>Ofatumumab Japanese Patients With CD20 Positive Follicular Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>INCLUSION CRITERIA : Signed Informed Consent . Histologically confirm relapsed refractory CD20 positive FL grade 13a 1 clearly demarcated lesion large diameter = 1.5 cm , CD5 , CD19 , CD20 CD23 positive relapse refractory CLL . Subjects must adequate blood , liver , kidney function . Subjects pass provide period last anticancer treatment screen ECOG Performance Status 02 Life expectancy 24 week screen EXCLUSION CRITERIA : Current past malignancy FL CLL within 5 year prior screen . Known Richter 's transformation Previous autologous stem cell transplantation within 24 week prior screen Previous allogeneic stem cell transplantation Known CNS involvement History significant cerebrovascular disease Current cardiac disease require medical treatment Chronic ongoing active infectious disease require systemic treatment Patients pleural effusion ascites detectable physical examination Positive serology test HBsAg , antiHBc antiHCV Known HIV positive Pregnant lactate woman Women childbearing potential male patient willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>CD20 positive</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>GSK1841157</keyword>
	<keyword>Japanese patient</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>